CYTK Dividend: Cytokinetics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

CYTK Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	87	18	7	94	70	55
Revenue Growth (YoY)	2,800%	157%	-93%	34%	27%	112%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	254	215	173	178	96	52
Research & Development	405	339	330	240	159	97
Operating Expenses	660	554	503	418	256	149
Other Non Operating Income (Expenses)	-18	-19	--	--	--	--
Pretax Income	-751	-589	-526	-389	-215	-127
Income Tax Expense	--	--	--	--	--	0
Net Income	-751	-589	-526	-389	-215	-127
Net Income Growth	30%	12%	35%	81%	69%	5%
Shares Outstanding (Diluted)	119.98	111.97	96.52	89.8	76.9	64.5
Shares Change (YoY)	2%	16%	7%	17%	19%	12%
EPS (Diluted)	-6.26	-5.26	-5.45	-4.33	-2.8	-1.97
EPS Growth	28%	-3%	26%	55%	42%	-7%
Free Cash Flow	-453	-399	-415	-310	-191	-2
Free Cash Flow Per Share	-3.77	-3.56	-4.29	-3.45	-2.48	-0.03
Gross Margin	--	--	--	--	--	--
Operating Margin	-657.47%	-2,977.77%	-7,085.71%	-344.68%	-265.71%	-169.09%
Profit Margin	-863.21%	-3,272.22%	-7,514.28%	-413.82%	-307.14%	-230.9%
Free Cash Flow Margin	-520.68%	-2,216.66%	-5,928.57%	-329.78%	-272.85%	-3.63%
EBITDA	-563	-527	-485	-319	-184	-92
EBITDA Margin	-647.12%	-2,927.77%	-6,928.57%	-339.36%	-262.85%	-167.27%
D&A For EBITDA	9	9	11	5	2	1
EBIT	-572	-536	-496	-324	-186	-93
EBIT Margin	-657.47%	-2,977.77%	-7,085.71%	-344.68%	-265.71%	-169.09%
Effective Tax Rate	--	--	--	--	--	0%